UBS initiated coverage of Omega Healthcare (OHI) with a Buy rating and $50 price target The firm expects positive estimate revisions for the company, driven by better than expected future investment volumes and strong EBITDAR coverage. Omega should see upside to investment volumes, driven by a “broad” investment total addressable market, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OHI:
- Omega Healthcare: Strong Buy Rating Driven by Strategic Investments and Positive Market Trends
- Omega Healthcare price target raised to $48 from $46 at BofA
- Omega Healthcare price target raised to $45 from $42 at Scotiabank
- Omega Healthcare price target raised to $50 from $45 at Citi
- Omega Healthcare Investors Reports Strong Q3 2025 Earnings